Home
About
Leadership
Technology
Pipeline
News
Careers
Contact

Recent Posts

Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
Artiva Announces Abstract Accepted for Presentation at the 64th American Society of Hematology Annual Meeting & Exposition
Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Archives

January 2023
November 2022
October 2022
September 2022
June 2022
May 2022
April 2022
March 2022
January 2022
October 2021
September 2021
August 2021
May 2021
April 2021
February 2021
January 2021
December 2020
November 2020
June 2020

Categories

Press Releases

Archives

January 2023
November 2022
October 2022
September 2022
June 2022
May 2022
April 2022
March 2022
January 2022
October 2021
September 2021
August 2021
May 2021
April 2021
February 2021
January 2021
December 2020
November 2020
June 2020

Category: Executives

Fred Aslan, M.D.

Jennifer Bush

Michael Faerm

Peter Flynn, Ph.D.

Thorsten Graef, M.D., Ph.D.

Christopher Horan

Eugene Helsel

Nooshin Hussainy

John Lim, Pharm.D.

Heather Raymon, Ph.D.

Privacy Policy
Terms

© Artiva Biotherapeutics, Inc., 2023

Sign up for news updates

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.AcceptPrivacy Policy